Replies to post #22219 on Relief Therapeutics Holding AG (RLFTF)

[dude iligence]

The EUA application covers the same type of patients whom FDA has already allowed to receive treatment under the Expanded Access protocol authorized by the Agency in July.  Tragically, we have found that many patients who might benefit from the Expanded Access protocol are hospitalized in centers that do not allow patients access to investigational drugs,” said Jonathan Javitt, MD, MPH, Chairman and CEO of NeuroRx, “Our staff is working around the clock to address requests for RLF-100™ under the appropriate mechanism.  All too often, patients of color and those of lower socioeconomic status are denied
access.”

-----

You still have to be on deathbed to get Aviptadil. Beauracratic organizations like VA and many smaller hospitals wont consider using drug like AVIPTADIL plus they threw in the race card.